A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yi, J.H. | - |
dc.contributor.author | Park, S. | - |
dc.contributor.author | Kim, J.H. | - |
dc.contributor.author | Won, Y.-W. | - |
dc.contributor.author | Lim, D.H. | - |
dc.contributor.author | Han, B. | - |
dc.contributor.author | Uhm, J. | - |
dc.contributor.author | Kim, H.S. | - |
dc.contributor.author | Jung, C.W. | - |
dc.contributor.author | Jang, J.H. | - |
dc.date.available | 2019-03-08T06:38:18Z | - |
dc.date.issued | 2018-01 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3170 | - |
dc.description.abstract | Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0-15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients. © Yi et al. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Impact Journals LLC | - |
dc.title | A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine | - |
dc.type | Article | - |
dc.identifier.doi | 10.18632/oncotarget.23823 | - |
dc.identifier.bibliographicCitation | Oncotarget, v.9, no.5, pp 6607 - 6614 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85040694310 | - |
dc.citation.endPage | 6614 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 6607 | - |
dc.citation.title | Oncotarget | - |
dc.citation.volume | 9 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Acute myeloid leukemia | - |
dc.subject.keywordAuthor | Decitabine | - |
dc.subject.keywordAuthor | Elderly patients | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.